Question 1

What is PONATINIB HYDROCHLORIDE used for?

Accepted Answer

PONATINIB HYDROCHLORIDE (brand name Iclusig) is a Electrolyte / Mineral indicated for accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, accelerated phase.

Question 2

How does PONATINIB HYDROCHLORIDE work?

Accepted Answer

PONATINIB HYDROCHLORIDE works through the following mechanism: 12.1 Mechanism of Action Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC 50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR::ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR::ABL when compared to controls..

Question 3

What are the most common side effects of PONATINIB HYDROCHLORIDE?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for PONATINIB HYDROCHLORIDE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is PONATINIB HYDROCHLORIDE the same as Iclusig?

Accepted Answer

Iclusig is a brand name for PONATINIB HYDROCHLORIDE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

PONATINIB HYDROCHLORIDE

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations